BI Strengthens Research Efforts In IO Stromal Biology And Retinal Disease
BI Enters Into Preclinical Deals With Northern Biologics And CDR-Life
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
